Carcinoma-associated hemolytic-uremic syndrome in a patient receiving 5-fluorouracil-adriamycin-mitomycin C combination chemotherapy.
A patient receiving the antitumor agent mitomycin C (MMC) in combination with 5-fluorouracil and adriamycin because of adenocarcinoma of Vater's papilla manifested hemolytic-uremic syndrome (HUS) after five cycles of 5-fluorouracil-adriamycin-MMC combination chemotherapy. The syndrome most likely was caused by MMC, since an association between HUS and the use of MMC has been observed. We report on the clinical course in such a patient and review the pertinent literature.
D000230:Adenocarcinoma / Q000150:complications* / Q000188:drug therapy; D014670:Ampulla of Vater; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001650:Bile Duct Neoplasms / Q000150:complications* / Q000188:drug therapy; D004317:Doxorubicin / Q000008:administration & dosage; D005472:Fluorouracil / Q000008:administration & dosage; D006463:Hemolytic-Uremic Syndrome / Q000139:chemically induced*; D006801:Humans; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000009:adverse effects*
D008937:Mitomycins; D016685:Mitomycin; D004317:Doxorubicin; D005472:Fluorouracil